K
Kara Kosakowski
Publications - 2
Citations - 46
Kara Kosakowski is an academic researcher. The author has contributed to research in topics: Lenalidomide & Neutropenia. The author has an hindex of 1, co-authored 2 publications receiving 46 citations.
Papers
More filters
Journal ArticleDOI
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.
Paul G. Richardson,Sundar Jagannath,Andrzej Jakubowiak,Sagar Lonial,Noopur Raje,Melissa Alsina,Irene M. Ghobrial,Amitabha Mazumder,Nikhil C. Munshi,David H. Vesole,Kathleen Colson,Mary McKenney,Laura E. Lunde,Sarah Kennedy,Kara Kosakowski,Constantine S. Mitsiades,Teru Hideshima,Robert Knight,Dixie-Lee Esseltine,Kenneth C. Anderson +19 more
TL;DR: This multi-center phase 2 study evaluated the efficacy and safety of Len/Bz/Dex (RVD) at the phase 1 MTD, and response rates according to baseline cytogenetics, disease stage, and prior therapies showed no significant differences according to adverse risk.
Journal ArticleDOI
Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)
Rachid Baz,Mohamad A. Hussein,Daniel C. Sullivan,J.L. Ochoa-Bayona,Monique A Hartley,Kenneth H. Shain,Taiga Nishihori,Jennifer Paleveda,Kara Kosakowski,William S. Dalton,Melissa Alsina +10 more
TL;DR: The combination of PLD, LEN and DEX is an active regimen in patients with NDMM and the dose reduction in PLD resulted in better tolerance without a compromise in efficacy due to less frequent treatment interruptions.